New treatment option for chronic inflammatory diseases: Remsima® - the first biosimilar infliximab;Neue Therapieoption bei chronisch-entzündlichen Erkrankungen: Remsima® – das erste Infliximab-Biosimilar

Verdauungskrankheiten

Volumn 33, Issue 2, 2015, Pages 108-109

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ARTICLE; CHRONIC ARTHRITIS;

EID: 84927928759     PISSN: 0174738X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Fachinformation Remsima®: Stand Dezember 2014.
2. Park W et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72: 1605-1612.
3. Yoo DH et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72: 1613-1620.
4. Park W et al. Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13. American College of Rheumatology/Association of Reproductive Health Professionals (ACR/ARHP), Annual Meeting, San Diego, CA, USA, 25.-30. Oktober 2013, Abstract #L15.
5. Yoo DH et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. American College of Rheumatology/ Association of Reproductive Health Professionals (ACR/ARHP) Annual Meeting, San Diego, CA, USA, 25.-30. Oktober 2013, Abstract #L1.
6. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/ human/002576/WC500151486.pdf (aufgerufen am: 26.01.2015).
7. Hanauer SB et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317): 1541-1549.
8. Reich K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366(9494): 1367-1374.